Literature DB >> 28485590

Structure-Activity Relationship of 2,4-Dichloro-N-(3,5-dichloro-4-(quinolin-3-yloxy)phenyl)benzenesulfonamide (INT131) Analogs for PPARγ-Targeted Antidiabetics.

Rebecca L Frkic, Yuanjun He1, Beatriz B Rodriguez, Mi Ra Chang1, Dana Kuruvilla1, Anthony Ciesla1, Andrew D Abell2, Theodore M Kamenecka1, Patrick R Griffin1, John B Bruning2.   

Abstract

Peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear receptor central to fatty acid and glucose homeostasis. PPARγ is the molecular target for type 2 diabetes mellitus (T2DM) therapeutics TZDs (thiazolidinediones), full agonists of PPARγ with robust antidiabetic properties, which are confounded with significant side effects. Partial agonists of PPARγ, such as INT131 (1), have displayed similar insulin-sensitizing efficacy as TZDs, but lack many side effects. To probe the structure-activity relationship (SAR) of the scaffold 1, we synthesized 14 analogs of compound 1 which revealed compounds with higher transcriptional potency for PPARγ and identification of moieties of the scaffold 1 key to high transcriptional potency. The sulfonamide linker is critical to activity, substitutions at position 4 of the benzene ring A were associated with higher transcriptional activity, substitutions at position 2 aided in tighter packing and activity, and the ring type and size of ring A affected the degree of activity.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28485590      PMCID: PMC5537074          DOI: 10.1021/acs.jmedchem.6b01727

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  25 in total

1.  Pharmacology and in vitro profiling of a novel peroxisome proliferator-activated receptor γ ligand, Cerco-A.

Authors:  Kenji Wakabayashi; Shinko Hayashi; Yumi Matsui; Takuo Matsumoto; Akihiro Furukawa; Masanori Kuroha; Naomi Tanaka; Tomoko Inaba; Shoichi Kanda; Jun Tanaka; Ryo Okuyama; Satoko Wakimoto; Tsuneaki Ogata; Kazushi Araki; Jun Ohsumi
Journal:  Biol Pharm Bull       Date:  2011       Impact factor: 2.233

2.  Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension.

Authors:  I Barroso; M Gurnell; V E Crowley; M Agostini; J W Schwabe; M A Soos; G L Maslen; T D Williams; H Lewis; A J Schafer; V K Chatterjee; S O'Rahilly
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

3.  Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator.

Authors:  Joel P Berger; Ann E Petro; Karen L Macnaul; Linda J Kelly; Bei B Zhang; Karen Richards; Alex Elbrecht; Bruce A Johnson; Gaochao Zhou; Thomas W Doebber; Chhabi Biswas; Mona Parikh; Neelam Sharma; Michael R Tanen; G Marie Thompson; John Ventre; Alan D Adams; Ralph Mosley; Richard S Surwit; David E Moller
Journal:  Mol Endocrinol       Date:  2003-01-16

4.  Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?

Authors:  Alex M DePaoli; Linda S Higgins; Robert R Henry; Christos Mantzoros; Fredrick L Dunn
Journal:  Diabetes Care       Date:  2014-04-10       Impact factor: 19.112

5.  Partial agonists activate PPARgamma using a helix 12 independent mechanism.

Authors:  John B Bruning; Michael J Chalmers; Swati Prasad; Scott A Busby; Theodore M Kamenecka; Yuanjun He; Kendall W Nettles; Patrick R Griffin
Journal:  Structure       Date:  2007-10       Impact factor: 5.006

6.  How good are my data and what is the resolution?

Authors:  Philip R Evans; Garib N Murshudov
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2013-06-13

7.  Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.

Authors:  Jang Hyun Choi; Alexander S Banks; Theodore M Kamenecka; Scott A Busby; Michael J Chalmers; Naresh Kumar; Dana S Kuruvilla; Youseung Shin; Yuanjun He; John B Bruning; David P Marciano; Michael D Cameron; Dina Laznik; Michael J Jurczak; Stephan C Schürer; Dušica Vidović; Gerald I Shulman; Bruce M Spiegelman; Patrick R Griffin
Journal:  Nature       Date:  2011-09-04       Impact factor: 49.962

Review 8.  Review of the Structural and Dynamic Mechanisms of PPARγ Partial Agonism.

Authors:  Alice J Kroker; John B Bruning
Journal:  PPAR Res       Date:  2015-09-08       Impact factor: 4.964

9.  An ERK/Cdk5 axis controls the diabetogenic actions of PPARγ.

Authors:  Alexander S Banks; Fiona E McAllister; João Paulo G Camporez; Peter-James H Zushin; Michael J Jurczak; Dina Laznik-Bogoslavski; Gerald I Shulman; Steven P Gygi; Bruce M Spiegelman
Journal:  Nature       Date:  2014-11-17       Impact factor: 49.962

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  3 in total

1.  Polypharmacology of N6-(3-Iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA) and Related A3 Adenosine Receptor Ligands: Peroxisome Proliferator Activated Receptor (PPAR) γ Partial Agonist and PPARδ Antagonist Activity Suggests Their Antidiabetic Potential.

Authors:  Jinha Yu; Seyeon Ahn; Hee Jin Kim; Moonyoung Lee; Sungjin Ahn; Jungmin Kim; Sun Hee Jin; Eunyoung Lee; Gyudong Kim; Jae Hoon Cheong; Kenneth A Jacobson; Lak Shin Jeong; Minsoo Noh
Journal:  J Med Chem       Date:  2017-08-28       Impact factor: 7.446

Review 2.  Pharmaceutical and medicinal significance of sulfur (SVI)-Containing motifs for drug discovery: A critical review.

Authors:  Chuang Zhao; K P Rakesh; L Ravidar; Wan-Yin Fang; Hua-Li Qin
Journal:  Eur J Med Chem       Date:  2018-11-22       Impact factor: 6.514

3.  16S rRNA Sequencing and Metagenomics Study of Gut Microbiota: Implications of BDB on Type 2 Diabetes Mellitus.

Authors:  Liang Zhang; Jiao Luo; Xiangqian Li; Shuju Guo; Dayong Shi
Journal:  Mar Drugs       Date:  2020-09-17       Impact factor: 5.118

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.